Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-06-28

Clinical Trial Update: Low-dose Intra-arterial Bevacizumab for Edema and Radiation Necrosis Therapeutic Intervention (LIBERTI) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating low-dose intra-arterial bevacizumab for radiation necrosis; the study has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Bevacizumab (bevacizumab)

Snippet

Sponsor: Norton Healthcare | Conditions: Radiation Necrosis | Phase 2 | Status: COMPLETED | Results posted: 2021-06-28